Revolution Medicines, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Revolution Medicines, Inc. (RVMD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 897.69 thousand shares for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-12.
Discontinued › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2020-11-12
- Revolution Medicines, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2020-09-30 was 66.32K shares.
- Revolution Medicines, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2020-06-30 was 170.25K shares.
- Revolution Medicines, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2020-03-31 was 661.12K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month |
|---|---|---|---|
| 2020-09-30 | 66.32K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | 236.57K shares derived: sum of 2 quarters · filed 2020-11-12 | 897.69K shares 10-Q · filed 2020-11-12 |
| 2020-06-30 | 170.25K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | 831.37K shares 10-Q · filed 2020-08-10 | |
| 2020-03-31 | 661.12K shares 10-Q · filed 2020-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |